Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.74 |
| ▸ | KDR | P35968 | 5/20 | 0.74 |
| ▸ | EGFR | P00533 | 4/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3455534 | 0.99 | PDGFRB (0.72) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL19789108 | 0.88 | HDAC1 (0.70) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL18088122 | 0.87 | HDAC1 (0.75) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL19789140 | 0.86 | HDAC1 (0.65) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL22432676 | 0.86 | HDAC1 (0.70) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL22432623 | 0.86 | HDAC1 (0.70) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL3106579 | 0.86 | PDGFRB (0.74) | PDGFRBKDREGFRHDAC1HDAC8 | |
| SCHEMBL3114969 | 0.85 | HDAC1 (0.80) | PDGFRBKDREGFRHDAC1HDAC8 | |
| Verubulin SCHEMBL29379614 | 0.85 | KDR (1.00) | PDGFRBKDREGFRHDAC1HDAC8 | |
| Verubulin SCHEMBL2232326 | 0.85 | KDR (1.00) | PDGFRBKDREGFRHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-03-12 | — | — | US | claimed |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| EP-1890677-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-11-08 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| JP-2007524637-A | — | — | 2007-08-30 | — | — | JP | claimed |
| WO-2006138608-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | PDGFRB 2687/4885KDR 2970/4885EGFR 1390/4885 |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2620/4885KDR 3716/4885EGFR 2915/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2627/4885KDR 3809/4885EGFR 2648/4885 |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | PDGFRB 2687/4885KDR 2970/4885EGFR 1390/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2620/4885KDR 3716/4885EGFR 2915/4885 |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | PDGFRB 2687/4885KDR 2970/4885EGFR 1390/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | PDGFRB 2620/4885KDR 3716/4885EGFR 2915/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2620/4885KDR 3716/4885EGFR 2915/4885 |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | PDGFRB 2687/4885KDR 2970/4885EGFR 1390/4885 |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | TUBB3, MAP2, MAPT | PDGFRB 944/4885KDR 1248/4885EGFR 1574/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PDGFRB 2620/4885KDR 3716/4885EGFR 2915/4885 |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | CASP3, CASP7, BAD | PDGFRB 2132/4885KDR 2664/4885EGFR 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.